Search for Clinical Trial Results

Sponsored By

Candidiasis - 83 Studies Found

Status Study
Completed Study Name: Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
Condition: Recurrent Vulvovaginal Candidiasis
Date: 2010-02-10
Interventions:
  • Biological: PEV7C1 capsule int
Completed Study Name: Arasertaconazole Nitrate Pessaries - Dose Finding Study for the Vulvovaginal Candidiasis (VVC) Treatment
Condition: Vulvovaginal Candidiasis
Date: 2010-06-09
Interventions:
  • Drug: arasertaconazole nitrate

Completed Study Name: A Randomized Study Evaluating the Therapeutic Equivalence of Two Butoconazole Nitrate Vaginal Cream, 2% Formulations
Condition: Vulvovaginal Candidiasis
Date: 2009-12-23
Interventions:
  • Drug: Butoconazole Nitrate Vaginal Cream

Completed Study Name: ProF-001_Phase IIa
Condition: Vulvovaginal Candidiasis (VVC)
Date: 2017-03-13
Interventions:
  • Drug: Candiplus Administration
Active, not recruiting Study Name: A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)
Condition: Recurrent Vulvovaginal Candidiasis
Date: 2014-10-08
Interventions:
  • Drug: VT-1161
  • Drug: Placebo
Completed Study Name: Antimycotic Prophylaxis in Pediatric Patients Following Allogeneic Stem Cell Transplantation
Condition:
  • Systemic Aspergillosis
  • Systemic Candidiasis

Date: 2009-12-28
Completed Study Name: Safety of Pregnant Subjects Exposed to Ibrexafungerp Including Infant Outcomes
Condition:
Date: 2025-08-10
Interventions: This is not an interventional study
Completed Study Name: Zinc-containing Vaginal Gel and Oral Fluconazole for Vulvovaginal Candidiasis.
Condition:
Date: 2025-08-10
Interventions: Women receive a single oral dose of fluconazole (150mg) followed by treatment with JUVIA zinc containing vaginal gel (daily for 2 weeks and twice per
Completed Study Name: Evaluate the Efficacy and Safety of Ruxolitinib on Hair Regrowth in Patients With Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (APECED)-Associated Alopecia Areata
Condition: Autoimmune Polyendocrinopathy Candidiasis Ectodermal Dystrophy (Apeced)
Date: 2025-08-10
Interventions: Ruxolitinib (Jakafi) is approved by the FDA for the treatment of intermediate or high-risk myelofibrosis in adults, polycythemia vera in adults who ha
NOT_YET_RECRUITING Study Name: Nitric Oxide Releasing Mouthwash (NORM) for the Management of Oropharyngeal Candidiasis
Condition: Candidiasis, Oral
Date: 2025-08-10
Interventions: Nitric Oxide Releasing Mouthwash will be self-administered by the participant three times throughout the day for 21 days.The intervention soluti
<<< Previous | Next >>>